Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia

Basit Öğe Kaydı
dc.authoridGuven, Esref Oguz/0000-0003-4919-9383
dc.contributor.authorGuven, Esref O.
dc.contributor.authorBalbay, Mevlana D.
dc.contributor.authorMete, Kilciler
dc.contributor.authorSerefoglu, Ege C.
dc.date.accessioned2024-09-18T20:04:23Z
dc.date.available2024-09-18T20:04:23Z
dc.date.issued2009
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractTo evaluate the acute effects of sildenafil (50 mg) on the micturation of men with erectile dysfunction (ED) and concomitant benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) using uroflowmetric parameters. A total of 68 male patients randomized into two groups (36 treatment, 32 control groups) with International Prostate Symptom Score (IPSS) greater than 7 and International Index of Erectile Dysfunction-erectile function domain score lower than 26 were enrolled in the study. Patients in the treatment group received a single dose of 50 mg of oral sildenafil. Patients in the control group received no treatment. Prevoiding urine volumes determined ultrasonographically and voided urine volumes were also recorded. Statistical comparisons were made with the use of analysis of variance (ANOVA). Mean ages were similar between treatment and control groups (60.4 +/- A 9.8 and 58.6 +/- A 8.3 years, respectively, P = 0.430). In the treatment group the maximum and average flow rates increased significantly (Q (max) from 15.6 +/- A 6.8 cc/s to 19.3 +/- A 7.2 cc/s, P < 0.0001; Q (avg) from 7.3 +/- A 3.0 cc/s to 9.1 +/- A 3.0 cc/s, P < 0.0001) with sildenafil administration, while other parameters studied remained unchanged. Despite the limitations of variations of uroflowmetry, this study showed that sildenafil improves Q (max) and Q (avg) in patients suffering from ED with concomitant BPH-LUTS. Long-term studies are needed to evaluate the effects on IPSS, side effects, and drug interactions.en_US
dc.identifier.doi10.1007/s11255-008-9423-y
dc.identifier.endpage292en_US
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue2en_US
dc.identifier.pmid18649004en_US
dc.identifier.scopus2-s2.0-67349088795en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage287en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-008-9423-y
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8131
dc.identifier.volume41en_US
dc.identifier.wosWOS:000265881000009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBenign prostate hyperplasiaen_US
dc.subjectLower urinary tract symptomsen_US
dc.subjectPhosphodiesterase inhibitorsen_US
dc.subjectSildenafilen_US
dc.subjectUroflowmetryen_US
dc.titleUroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full text
Boyut:
166.68 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu